InProcess-LSP attracts growth financing for NanoFlowSizer portfolio expansion and scaling sales.

February 15, 2023

After introduction of the GMP compliant version for pharma industry in 2022, expansion of the NFS portfolio is a logical step for InProcess-LSP to address today’s most demanding particle size characterization needs both in industry and in academic R&D. Capabilities of the advanced OCT core technology of the NFS are extensive and will continuously drive new opportunities for relevant and advanced characterization of nano and microparticle suspensions. To realize these opportunities, InProcess-LSP will further scale up the organization to support ongoing developments and portfolio extensions in 2023. This has now been facilitated by a combined investment via additional equity of the current loyal investors Brabantse Development Agency (BOM) and Value Creation Capital (VCC), and by an additional nondilutive financing part by Rabobank and subsidiary De Lage Landen (DLL).

Read the full article here.